• News by Topic

  • News by Topic

  • Relationships news

  • Mind and body

    "Live as if your were to die tomorrow. Learn as if you were to live forever. You must learn to be still in the midst of activity and be vibrantly alive in repose."

    --Gandhi

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Vote!

FDA Approves New Three-Month Long-Acting Antipsychotic Invega Trinza

The FDA has approved Invega Trinza (paliperidone palmitate), a long-acting atypical antipsychotic intended to treat schizophrenia, from Janssen Pharmaceuticals Inc.The approval of the injectable antipsychotic, which remains active in the body for three months, was based on results from a two-year maintenance trial with 506 patients diagnosed with schizophrenia. The analysis, published March 29 in JAMA Psychiatry, showed that patients who were administered Invega Trinza were statistically less likely to relapse than those who were administered placebo. The most common adverse effects of the medication included injection-site reactions, weight gain,...

read more...

Share |

Published By: Psychiatric News - Friday, 22 May, 2015

Copyright © 2016 Psychology One. All rights reserved. This site is for education & information purposes. This site is not a substitute for professional psychological, medical or psychiatric treatment.